PMID- 28543698
OWN - NLM
STAT- MEDLINE
DCOM- 20170821
LR  - 20180926
IS  - 1097-0142 (Electronic)
IS  - 0008-543X (Linking)
VI  - 123
IP  - S11
DP  - 2017 Jun 1
TI  - Adoptive T cell therapy: An overview of obstacles and opportunities.
PG  - 2154-2162
LID - 10.1002/cncr.30491 [doi]
AB  - The therapeutic potential of adoptive cell therapy (ACT) in cancer patients was
      first acknowledged 3 decades ago, but it was an esoteric approach at the time. In
      recent years, technological advancements have transformed ACT into a viable
      therapeutic option that can be curative in some patients. In fact, current ACT
      response rates are 80% to 90% for hematological malignancies and 30% for
      metastatic melanoma refractory to multiple lines of therapy. Although these
      results are encouraging, there is still much to be done to fulfill ACT's
      potential, specifically with regard to improving clinical efficacy, expanding
      clinical indications, reducing toxicity, and increasing production and
      cost-effectiveness. This review addresses the current major obstacles to ACT and 
      presents potential solutions. Cancer 2017;123:2154-62. (c) 2017 American Cancer
      Society.
CI  - (c) 2017 American Cancer Society.
FAU - Baruch, Erez Nissim
AU  - Baruch EN
AD  - The Ella Lemelbaum Institute of Immuno-oncology, Institute of Oncology, Sheba
      Medical Center, Tel Hashomer, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Berg, Amy Lauren
AU  - Berg AL
AD  - The Ella Lemelbaum Institute of Immuno-oncology, Institute of Oncology, Sheba
      Medical Center, Tel Hashomer, Israel.
FAU - Besser, Michal Judith
AU  - Besser MJ
AD  - The Ella Lemelbaum Institute of Immuno-oncology, Institute of Oncology, Sheba
      Medical Center, Tel Hashomer, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Schachter, Jacob
AU  - Schachter J
AD  - The Ella Lemelbaum Institute of Immuno-oncology, Institute of Oncology, Sheba
      Medical Center, Tel Hashomer, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
FAU - Markel, Gal
AU  - Markel G
AD  - The Ella Lemelbaum Institute of Immuno-oncology, Institute of Oncology, Sheba
      Medical Center, Tel Hashomer, Israel.
AD  - Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
AD  - Talpiot Medical Leadership Program, Sheba Medical Center, Tel Hashomer, Israel.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Cancer
JT  - Cancer
JID - 0374236
RN  - 0 (Antigens, Neoplasm)
SB  - AIM
SB  - IM
MH  - Adoptive Transfer/adverse effects/*methods
MH  - Antigens, Neoplasm/immunology
MH  - Humans
MH  - Lymphocytes, Tumor-Infiltrating/*transplantation
MH  - Melanoma/*therapy
MH  - T-Lymphocytes/*transplantation
MH  - T-Lymphocytes, Regulatory/immunology
MH  - Tumor Escape/*immunology
MH  - Tumor Microenvironment/*immunology
OTO - NOTNLM
OT  - *T cell receptor
OT  - *adoptive cellular immunotherapy
OT  - *chimeric antigen receptor
OT  - *immunotherapy
OT  - *melanoma
OT  - *tumor-infiltrating lymphocytes
EDAT- 2017/05/26 06:00
MHDA- 2017/08/22 06:00
CRDT- 2017/05/26 06:00
PHST- 2016/10/08 00:00 [received]
PHST- 2016/11/11 00:00 [revised]
PHST- 2016/11/15 00:00 [accepted]
PHST- 2017/05/26 06:00 [entrez]
PHST- 2017/05/26 06:00 [pubmed]
PHST- 2017/08/22 06:00 [medline]
AID - 10.1002/cncr.30491 [doi]
PST - ppublish
SO  - Cancer. 2017 Jun 1;123(S11):2154-2162. doi: 10.1002/cncr.30491.